Results · Jul-Sep 2026 · filed 17 Oct 2026
Rossari Biotech Q2 FY27 results
Sales grew 19% to ₹698 crore from ₹586 crore in Jul-Sep 2025.
Operating profit grew 21% to ₹87 crore, an operating margin of 12.5% (up 0.2 points from a year ago).
Net profit grew 6% to ₹38.9 crore from ₹36.9 crore in Jul-Sep 2025.
Against Apr-Jun 2026: sales +0%, net profit +11%.
Jul-Sep 2026 vs a year ago
| ₹ crore | Jul-Sep 2026 | Jul-Sep 2025 | Change |
|---|---|---|---|
| Sales | 697.6 | 586.1 | +19% |
| Operating profit (EBITDA) | 87.0 | 71.9 | +21% |
| Operating margin | 12.5% | 12.3% | +0.2 pts |
| Net profit | 38.9 | 36.9 | +6% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 8 quarters
Filings that week
- 19 Oct 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- 19 Oct 2026Announcement under Regulation 30 (LODR)-Press Release / Media Release
- 19 Oct 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 18 Oct 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 17 Oct 2026Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2026.
- 17 Oct 2026Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
- 17 Oct 2026Board Meeting Outcome for Board Meeting Outcome For Board Meeting Held On October 17, 2026
- 14 Oct 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.